Tags

Type your tag names separated by a space and hit enter

Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life.
Pharmacol Res Perspect. 2020 Aug; 8(4):e00621.PR

Abstract

The aim of the study is to investigate the patterns of polypharmacy, clinical-relevant drug-drug interactions (DDIs), and potentially inappropriate medicines (PIMs), and whether polypharmacy, potential serious clinically-relevant DDIs, or PIMs can be associated with low quality of life (QoL) index scores of older adults with type 2 diabetes (T2D). A cross-sectional study was conducted using data of 670 elderly T2D sub-cohort from a nationwide pharmacy-based intensive monitoring study of inception cohort of T2D in Portugal. 72.09% were found on polypharmacy (≥5 medicines). Participants on polypharmacy were mostly females (P = .0115); more obese (P = .0131); have more comorbid conditions (P < .0001); more diabetes complications (P < .0001); and use more of glucose lowering drugs (P = .0326); insulin (P < .0001); chronic medicines (P < .0001); and have higher diabetes duration (P = .0088) than those without polypharmacy. 10.59% of the participants were found to have potential serious clinically relevant DDIs. The most frequent drug-combinations were angiotensin-converting enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARBs), aspirin with Selective serotonin reuptake inhibitors (SSRIs), and clopidogrel with calcium channel blockers. PIMs are found in 36.11% of the participants. The most common PIMs were benzodiazepines, long-acting sulfonylureas, and iron overdose. The adjusted multivariate models show that Polypharmacy, PIMs, and potential serious clinically relevant DDIs were associated with lower QoL index scores (OR 1.80 95% CI 1.15-2.82), (OR 1.57 95% CI 1.07-2.28), and (OR 1.34 95% CI 0.73-2.48) respectively. The study shows that polypharmacy, potential serious clinical-relevant DDIs, and PIMs may correlate with risk of reduced health related QoL outcome of older adults with T2D.

Authors+Show Affiliations

Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.Centre for Health Evaluation & Research (CEFAR), Lisbon, Portugal.Centre for Health Evaluation & Research (CEFAR), Lisbon, Portugal.Nova Medical School, Nova University of Lisbon, Lisbon, Portugal. Portuguese Diabetes Association (APDP), Lisbon, Portugal.Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32618136

Citation

Al-Musawe, Labib, et al. "Polypharmacy, Potentially Serious Clinically Relevant Drug-drug Interactions, and Inappropriate Medicines in Elderly People With Type 2 Diabetes and Their Impact On Quality of Life." Pharmacology Research & Perspectives, vol. 8, no. 4, 2020, pp. e00621.
Al-Musawe L, Torre C, Guerreiro JP, et al. Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacol Res Perspect. 2020;8(4):e00621.
Al-Musawe, L., Torre, C., Guerreiro, J. P., Rodrigues, A. T., Raposo, J. F., Mota-Filipe, H., & Martins, A. P. (2020). Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacology Research & Perspectives, 8(4), e00621. https://doi.org/10.1002/prp2.621
Al-Musawe L, et al. Polypharmacy, Potentially Serious Clinically Relevant Drug-drug Interactions, and Inappropriate Medicines in Elderly People With Type 2 Diabetes and Their Impact On Quality of Life. Pharmacol Res Perspect. 2020;8(4):e00621. PubMed PMID: 32618136.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. AU - Al-Musawe,Labib, AU - Torre,Carla, AU - Guerreiro,Jose Pedro, AU - Rodrigues,Antonio Teixeira, AU - Raposo,Joao Filipe, AU - Mota-Filipe,Helder, AU - Martins,Ana Paula, PY - 2020/05/05/received PY - 2020/05/28/revised PY - 2020/06/09/accepted PY - 2020/7/4/entrez PY - 2020/7/4/pubmed PY - 2020/7/4/medline KW - Type 2 diabetes KW - drug-drug interactions KW - elderly KW - polypharmacy KW - potentially inappropriate medicines KW - quality of life SP - e00621 EP - e00621 JF - Pharmacology research & perspectives JO - Pharmacol Res Perspect VL - 8 IS - 4 N2 - The aim of the study is to investigate the patterns of polypharmacy, clinical-relevant drug-drug interactions (DDIs), and potentially inappropriate medicines (PIMs), and whether polypharmacy, potential serious clinically-relevant DDIs, or PIMs can be associated with low quality of life (QoL) index scores of older adults with type 2 diabetes (T2D). A cross-sectional study was conducted using data of 670 elderly T2D sub-cohort from a nationwide pharmacy-based intensive monitoring study of inception cohort of T2D in Portugal. 72.09% were found on polypharmacy (≥5 medicines). Participants on polypharmacy were mostly females (P = .0115); more obese (P = .0131); have more comorbid conditions (P < .0001); more diabetes complications (P < .0001); and use more of glucose lowering drugs (P = .0326); insulin (P < .0001); chronic medicines (P < .0001); and have higher diabetes duration (P = .0088) than those without polypharmacy. 10.59% of the participants were found to have potential serious clinically relevant DDIs. The most frequent drug-combinations were angiotensin-converting enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARBs), aspirin with Selective serotonin reuptake inhibitors (SSRIs), and clopidogrel with calcium channel blockers. PIMs are found in 36.11% of the participants. The most common PIMs were benzodiazepines, long-acting sulfonylureas, and iron overdose. The adjusted multivariate models show that Polypharmacy, PIMs, and potential serious clinically relevant DDIs were associated with lower QoL index scores (OR 1.80 95% CI 1.15-2.82), (OR 1.57 95% CI 1.07-2.28), and (OR 1.34 95% CI 0.73-2.48) respectively. The study shows that polypharmacy, potential serious clinical-relevant DDIs, and PIMs may correlate with risk of reduced health related QoL outcome of older adults with T2D. SN - 2052-1707 UR - https://www.unboundmedicine.com/medline/citation/32618136/Polypharmacy,_potentially_serious_clinically_relevant_drug-drug_interactions,_and_inappropriate_medicines_in_elderly_people_with_type_2_diabetes_and_their_impact_on_quality_of_life L2 - https://doi.org/10.1002/prp2.621 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.